← All organizations
Highest phase reached
Phase 3
Timeline
Drugs by trial phase (25 distinct, 40 trials)
Phase 3 (12 own, 0 via acquisition)
Phase 2 (7 own, 0 via acquisition)
Phase 1 (2 own, 0 via acquisition)
Other trials (4 own, 0 via acquisition)
Indications
Studied for
- Acute Pain
- Angiofibroma
- Apnea
- Autism Spectrum Disorder
- Autistic Disorder
- Behcet Syndrome
- Child Development Disorders, Pervasive
- Cytomegalovirus Infections
- Disease
- Dysmenorrhea
- Endometriosis
- Epilepsy
- Glioblastoma
- Glioma
- Hepatolenticular Degeneration
- Herpes Zoster
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Neuralgia
- Neurodevelopmental Disorders
- Neurofibroma
- Neurofibromatoses
- Neurofibromatosis 1
- Parasomnias
- Premature Birth
- Sclerosis
- Sleep Wake Disorders
- Tuberous Sclerosis
Marketed drugs (1)
Recent trials (40)
- NCT06940895CollaboratorPhase 2Mar 1, 2025
- NCT06448039CollaboratorPhase 1/Phase 2Jun 15, 2024
- NCT05480553Lead sponsorPhase 3Aug 5, 2022
- NCT05495425Lead sponsorPhase 3Jun 1, 2022
- NCT04962893CollaboratorPhase 2Jun 26, 2021
- NCT04818281CollaboratorPhase 1Mar 27, 2021
- NCT04671472Lead sponsorPhase 3Feb 8, 2021
- NCT04642950Lead sponsorPhase 2/Phase 3Dec 17, 2020
- NCT04374955CollaboratorN/AJul 31, 2020
- NCT04503863Lead sponsorPhase 1Jul 20, 2020
- NCT04461886Lead sponsorPhase 3Jul 8, 2020
- NCT04225923Lead sponsorPhase 2Apr 30, 2020
- NCT04203862Lead sponsorPhase 1Nov 19, 2019
- NCT04139330Lead sponsorPhase 2Oct 25, 2019
- NCT03972462Lead sponsorPhase 1May 31, 2019
Details
- Founded
- Tokyo, JP Jan 1, 2003
- Last known activity
- Mar 1, 2025